Our Patients

Put simply, our customers are seeking clean, natural, organic cannabis to treat a series of illnesses and ailments. They are seeking alternatives to commercially produced medicines (including cannabis products).

Let's have a closer look at what cannabis users look like.

Deloitte’s ‘Cannabis Report’ found that 74% of people surveyed have prior experience with recreational cannabis, and 41% have consumed it in the past five years.

Cannabis consumers fall into several categories including experimental, recreational and medical. The sector that MOCA focuses on presently is medical patients who consume cannabis for a definitive purpose.

The Patient is a medical cannabis user who tends to be somewhat more selective and discerning than the recreational consumers. MOCA views this group as better informed on treatment options.

These consumers seek overall pain relief, and are more likely to shy away from the branding geared towards many forms of recreational use. They are more likely to treat cannabis just like any other medicine they are prescribed to take.

Medical cannabis is typically used by the patient to relax muscles and relieve headaches, migraines, and general body pain. And though the traditional medical cannabis user may be prescribed the product for a variety of symptoms associated with chronic illness, a growing number of patients are being prescribed cannabis to treat insomnia and to relieve general anxiety and stress brought on by the day to day.

The Patient uses and consumes cannabis for a definitive purpose, and ultimately is not looking for something to take to have fun; they are looking for something they can take to treat an ailment, disease, or other condition. For this type of cannabis buyer, the product is meant to be therapeutic, not as a way to ‘chill out’ in a large group setting or have a totally life altering experience.

MOCA embraces the emerging science that shows that organic cultivation leads to terpene profiles that are two times that of conventional production. Certified organic standards and environmental regulations with respect to cannabis production, organic cannabis contains higher levels of medicinal cannabinoids and terpenes, and offers a more balanced “wellness feel" to the cannabis experience.

In contrast, irradiation is a common practice in manufacturing cannabis products. Irradiation is a process which kills all life within a cannabis flower before distribution. It has been found to have an impact on the terpenes which are the essential oils found in cannabis.

Irradiation is clearly not organic practice.

So why does MOCA target organic cannabis products?

The Patients can be divided into two groups, organic cannabis patients and non organic cannabis patients. We have found that the first group has researched online the benefits of organic medicines. This group seeks medicines that are as natural as possible to treat serious illnesses. They are seeking ethically sustainable products that embrace the spirit of medical cannabis. As you will see, this group of consumers is growing rapidly.

Hill and Knowlton report that environmental, social and governance indicators have never been more important to large investors. The same research found that 57% of medical patients prefer organic cannabis. The survey found 43% of recreational users had the same preference and were willing to pay a premium for the product. Reference

It is in this buoyant and dynamic market context that Medicinal Organic Cannabis Australia (MOCA) Pty Ltd, (the Company) is operating. At MOCA, we believe that as the cannabis industry moves out of the darkness and into the light, it has the potential to be an agricultural leader when it comes to clean growing and converting to water-saving farming techniques.